A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

We previously reported that the combination of two safe proteostasis regulators, cysteamine and epigallocatechin gallate (EGCG), can be used to improve deficient expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in patients homozygous for the CFTR Phe508del mutation. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosco, A, De Gregorio, F, Esposito, S, De Stefano, D, Sana, I, Ferrari, E, Sepe, A, Salvadori, L, Buonpensiero, P, Di Pasqua, A, Grassia, R, Leone, C A, Guido, S, De Rosa, G, Lusa, S, Bona, G, Stoll, G, Maiuri, M C, Mehta, A, Kroemer, G, Maiuri, L, Raia, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947669/
https://www.ncbi.nlm.nih.gov/pubmed/27035618
http://dx.doi.org/10.1038/cdd.2016.22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947669/
https://www.ncbi.nlm.nih.gov/pubmed/27035618
http://dx.doi.org/10.1038/cdd.2016.22

Ejemplares similares